This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
4 Mar 2011

ITI & Takeda Ink $750M Drug Discovery Pact

Intra-Cellular Therapies, Inc. and Takeda Pharmaceutical Company Limited announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors.

Intra-Cellular Therapies announced that it struck a preclinical discovery deal with Takeda to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors for cognitive impairment associated with schizophrenia.

 

ITI has retained the option to co-promote with Takeda in the United States. ITI will be eligible for $500 million in development milestones plus another $250 million in sales-based milestones, along with tiered royalty payments.

Related News